Muzaffar Qazilbash
@transplantdoc.bsky.social
Reposted by Muzaffar Qazilbash
Sarah Cannon Transplant and Cellular Therapy Registry work led by Drs Rao and Battiwalla comparing bendamustine vs. Flu/Cy LD chemo prior to #CART in #Lymphoma. This was done during period of Flu shortage. No difference in OS, PFS, CRS, ICANS.
www.astctjournal.org/article/S266...
www.astctjournal.org/article/S266...
Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma
Chimeric antigen receptor T-cell (CAR-T) therapy is a widely adopted treatment for
relapsed/refractory non-Hodgkin lymphomas (NHLs)1. FDA-approved CAR-T products for
large B-cell lymphoma (LBCL) inclu...
www.astctjournal.org
March 24, 2025 at 11:16 PM
Sarah Cannon Transplant and Cellular Therapy Registry work led by Drs Rao and Battiwalla comparing bendamustine vs. Flu/Cy LD chemo prior to #CART in #Lymphoma. This was done during period of Flu shortage. No difference in OS, PFS, CRS, ICANS.
www.astctjournal.org/article/S266...
www.astctjournal.org/article/S266...
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study - The Lancet Haematology #mmsm #bmtsm www.thelancet.com/journals/lan...
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
Talquetamab continued to demonstrate high overall response rates in heavily pretreated
patients with relapsed or refractory multiple myeloma with longer follow-up in this
post-hoc analysis. Overall re...
www.thelancet.com
March 20, 2025 at 3:39 AM
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study - The Lancet Haematology #mmsm #bmtsm www.thelancet.com/journals/lan...
Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity - Clinical Lymphoma, Myeloma and Leukemia www.clinical-lymphoma-myeloma-leukemia.com/article/S215...
Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity
MicroabstractOur study evaluated the efficacy and safety of reduced-dose melphalan
(Mel140) versus high-dose melphalan (Mel200) in 233 multiple myeloma patients undergoing
first autologous stem cell t...
www.clinical-lymphoma-myeloma-leukemia.com
March 20, 2025 at 3:32 AM
Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity - Clinical Lymphoma, Myeloma and Leukemia www.clinical-lymphoma-myeloma-leukemia.com/article/S215...
Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity #mmsm #bmtsm www.clinical-lymphoma-myeloma-leukemia.com/article/S215...
Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity
MicroabstractOur study evaluated the efficacy and safety of reduced-dose melphalan
(Mel140) versus high-dose melphalan (Mel200) in 233 multiple myeloma patients undergoing
first autologous stem cell t...
www.clinical-lymphoma-myeloma-leukemia.com
March 20, 2025 at 3:27 AM
Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity #mmsm #bmtsm www.clinical-lymphoma-myeloma-leukemia.com/article/S215...
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies #mmsm #bmtsm jhoonline.biomedcentral.com/articles/10....
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies - Journal of Hematology & Oncology
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of patients with relapsed/refractory (R/R) hematologic malignancies, including B-cell lymphomas and multiple myeloma (MM...
jhoonline.biomedcentral.com
March 20, 2025 at 3:17 AM
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies #mmsm #bmtsm jhoonline.biomedcentral.com/articles/10....
Full article: Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable www.tandfonline.com/doi/full/10....
Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable
In less than a decade since their first approval, chimeric antigen receptor T-cell (CAR-T) therapies have moved into earlier lines of therapy, shifting administration from an inpatient to an outpat...
www.tandfonline.com
March 20, 2025 at 3:08 AM
Full article: Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable www.tandfonline.com/doi/full/10....
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | New England Journal of Medicine www.nejm.org/doi/full/10....
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | NEJM
Bloodstream infections are associated with substantial morbidity and mortality. Early,
appropriate antibiotic therapy is important, but the duration of treatment is uncertain.
In a multicenter, non...
www.nejm.org
March 20, 2025 at 3:03 AM
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | New England Journal of Medicine www.nejm.org/doi/full/10....
Stem Cell Transplantation & Cellular Therapy Fellowship- UT MD Anderson Cancer Center
careercenter.asco.org/job/7623735/...
careercenter.asco.org/job/7623735/...
careercenter.asco.org
February 25, 2025 at 10:17 PM
Stem Cell Transplantation & Cellular Therapy Fellowship- UT MD Anderson Cancer Center
careercenter.asco.org/job/7623735/...
careercenter.asco.org/job/7623735/...
Dara+ Len vs. Len alone as maintenance post autoSCT in NDMM: the AURIGA study. Dara + Len was associated with a better MRD -ve conversion and 30-month PFS #bmtsm #mmsm doi.org/10.1182/bloo...
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
Key PointsD-R maintenance improved MRD-negative conversion rate in patients with NDMM who were MRD-positive after transplant vs R maintenance.PFS favored D
doi.org
February 11, 2025 at 4:32 AM
Dara+ Len vs. Len alone as maintenance post autoSCT in NDMM: the AURIGA study. Dara + Len was associated with a better MRD -ve conversion and 30-month PFS #bmtsm #mmsm doi.org/10.1182/bloo...
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | New England Journal of Medicine #mmsm #bmtsm @nejm.org www.nejm.org/doi/full/10....
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o...
www.nejm.org
February 7, 2025 at 12:22 AM
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | New England Journal of Medicine #mmsm #bmtsm @nejm.org www.nejm.org/doi/full/10....
Highlights of ASH 2024: Focus on Multiple Myeloma #ASH24 #mmsm #bmtsm opmed.doximity.com/articles/hig...
Highlights of ASH 2024: Focus on Multiple Myeloma
According to the Surveillance, Epidemiology, and End Results Program registry, approximately 36,000 patients are annually diagnosed with multiple m...
opmed.doximity.com
December 23, 2024 at 10:27 PM
Highlights of ASH 2024: Focus on Multiple Myeloma #ASH24 #mmsm #bmtsm opmed.doximity.com/articles/hig...
GMMG-HD7 trial: Isa-VRD vs. VRD in transplant-eligible NDMM, N=662, Significantly higher MRD -ve (66 vs. 48%) and longer PF (3-year PFS: 88 vs. 71%) with Isa-VRD #bmtsm #mmsm ascopubs.org/doi/10.1200/JC…
https://ascopubs.org/doi/10.1200/JC…
December 15, 2024 at 5:44 PM
GMMG-HD7 trial: Isa-VRD vs. VRD in transplant-eligible NDMM, N=662, Significantly higher MRD -ve (66 vs. 48%) and longer PF (3-year PFS: 88 vs. 71%) with Isa-VRD #bmtsm #mmsm ascopubs.org/doi/10.1200/JC…
High serum BCMA level and high metabolic tumor volume measured by PET/CT predict inferior PFS in RRMM treated with anti-BCMA CAR-T. Poor correlation seen between the two tests #bmtsm #mmsm ashpublications.org/blood/articl...
Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes
Key Points. High sBCMA and high MTV predict for inferior outcomes and increased severity toxicities in RRMM treated with anti-BCMA CAR-TDiscrepant results
ashpublications.org
December 15, 2024 at 5:43 PM
High serum BCMA level and high metabolic tumor volume measured by PET/CT predict inferior PFS in RRMM treated with anti-BCMA CAR-T. Poor correlation seen between the two tests #bmtsm #mmsm ashpublications.org/blood/articl...
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience. N=1304, Gain 1q seen in 43% patients, all others in <10%. t(4;14), del 17p (>20% cells) and Gain 1q => shorter PFS and OS #bmtsm #mmsm onlinelibrary.wiley.com/doi/10.1002/...
High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience
This study examines the impact of cytogenetic abnormalities and their co-segregation on the prognosis of newly diagnosed multiple myeloma patients. The analysis included 1304 patients from four diffe...
onlinelibrary.wiley.com
December 15, 2024 at 5:41 PM
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience. N=1304, Gain 1q seen in 43% patients, all others in <10%. t(4;14), del 17p (>20% cells) and Gain 1q => shorter PFS and OS #bmtsm #mmsm onlinelibrary.wiley.com/doi/10.1002/...
#ASH24 First-in-human, dose escalation study of ISB 2001 (BCMAxCD38xCD3 trispecific antibody) in RRMM. N=14, CRS: 71% (gr 1 or 2), ORR: 75%. #mmsm #bmtsm ash.confex.com/ash/2024/web...
Paper: First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
ash.confex.com
December 5, 2024 at 3:51 AM
#ASH24 First-in-human, dose escalation study of ISB 2001 (BCMAxCD38xCD3 trispecific antibody) in RRMM. N=14, CRS: 71% (gr 1 or 2), ORR: 75%. #mmsm #bmtsm ash.confex.com/ash/2024/web...
#ASH24 Cevostamab (anti-FcR5H bispecific), in RRMM. N=167, prior LOT: 6, 57% with prior anti-BCMA Rx. EMD: 28%. ORR: 43% (60% in anti-BCMA-naive). Infections: 53.9% #mmsm #bmtsm #ASH24 ash.confex.com/ash/2024/web...
Paper: Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
ash.confex.com
December 5, 2024 at 3:30 AM
#ASH24 Cevostamab (anti-FcR5H bispecific), in RRMM. N=167, prior LOT: 6, 57% with prior anti-BCMA Rx. EMD: 28%. ORR: 43% (60% in anti-BCMA-naive). Infections: 53.9% #mmsm #bmtsm #ASH24 ash.confex.com/ash/2024/web...
#ASH24 Cilta-cel vs. SOC in RRMM (1-3 lines), CARTITUDE-4; MRD- update. N=419, median F/U: 33.6 months. >3-fold increase in MRD -ve with cilta-cel #mmsm #bmtsm ash.confex.com/ash/2024/web...
Paper: Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) N...
ash.confex.com
December 4, 2024 at 4:47 AM
#ASH24 Cilta-cel vs. SOC in RRMM (1-3 lines), CARTITUDE-4; MRD- update. N=419, median F/U: 33.6 months. >3-fold increase in MRD -ve with cilta-cel #mmsm #bmtsm ash.confex.com/ash/2024/web...
#ASH24 Phase II trial of Anito-cel in RRMM #mmsm #bmtsm N=58, ORR: 95%, CR: 62%, MRD- 10^-5: 92%, CRS: 84%, no delayed neurotoxicity #mmsm #bmtsm ash.confex.com/ash/2024/web...
Paper: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
ash.confex.com
December 4, 2024 at 4:34 AM
#ASH24 Phase I clinical trial of Anti-BCMA/GPRC5D bispecific CAR T-Cells in RRMM with Extramedullary Disease. N=6, ORR: 100% (CR: 50%) #mmsm #bmtsm ash.confex.com/ash/2024/web...
Paper: A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease
ash.confex.com
December 4, 2024 at 4:17 AM
#ASH24 Phase I clinical trial of Anti-BCMA/GPRC5D bispecific CAR T-Cells in RRMM with Extramedullary Disease. N=6, ORR: 100% (CR: 50%) #mmsm #bmtsm ash.confex.com/ash/2024/web...
The best books of 2024, as chosen by The Economist www.economist.com/culture/2024...
The best books of 2024, as chosen by The Economist
Readers will never think the same way again about games, horses and spies
www.economist.com
December 4, 2024 at 4:00 AM
The best books of 2024, as chosen by The Economist www.economist.com/culture/2024...
Reposted by Muzaffar Qazilbash
ASTCT recently released a special issue of Transplantation and Cellular Therapy dedicated to the latest research, challenges and innovations in chronic #GVHD management. #bmtsm www.astctjournal.org/issue/S2666-...
November 30, 2024 at 11:03 PM
ASTCT recently released a special issue of Transplantation and Cellular Therapy dedicated to the latest research, challenges and innovations in chronic #GVHD management. #bmtsm www.astctjournal.org/issue/S2666-...
CULTURE: The Story of Us, From Cave Art to K-Pop, by Martin Puchner: Book Review www.nytimes.com/2023/02/07/b...
Culture as a Centuries-Long Game of Telephone (Published 2023)
Martin Puchner’s new book is a forceful rebuke to those who argue that culture can be owned by groups, nations, religions or races.
www.nytimes.com
November 30, 2024 at 9:28 PM
CULTURE: The Story of Us, From Cave Art to K-Pop, by Martin Puchner: Book Review www.nytimes.com/2023/02/07/b...
The Dawn of Everything by David Graeber and David Wengrow: Book Review @theguardian1.bsky.social www.theguardian.com/books/2021/o...
The Dawn of Everything by David Graeber and David Wengrow review – inequality is not the price of civilisation
An archaeologist and an anthropologist dismantle received wisdom about the way early societies operated
www.theguardian.com
November 30, 2024 at 9:23 PM
The Dawn of Everything by David Graeber and David Wengrow: Book Review @theguardian1.bsky.social www.theguardian.com/books/2021/o...
The Invention of Good and Evil: A World History of Morality. By Hanno Sauer. Book review @theeconomistevents.bsky.social www.economist.com/culture/2024...
How humans invented good and evil, and may reinvent both
Over thousands of years humans domesticated themselves
www.economist.com
November 30, 2024 at 9:19 PM
The Invention of Good and Evil: A World History of Morality. By Hanno Sauer. Book review @theeconomistevents.bsky.social www.economist.com/culture/2024...
Optimal infused CD34+ cell dose in NDMM patients undergoing upfront autoHCT: >2.5 × 106 cells/kg. Phenomenal work by #orenpasvolsky @mdanderson.bsky.social #mmsm #bmtsm www.nature.com/articles/s41...
November 30, 2024 at 9:11 PM
Optimal infused CD34+ cell dose in NDMM patients undergoing upfront autoHCT: >2.5 × 106 cells/kg. Phenomenal work by #orenpasvolsky @mdanderson.bsky.social #mmsm #bmtsm www.nature.com/articles/s41...